Trinity Biotech Plc Sponsored ADR Class A Stock

$1.40

4.11%

Nasdaq, Sep 02, 10:09 pm CET

ISIN

US8964383066

Symbol

TRIB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health Care Equipment & Services

Industry

Health Care Equipment & Supplies

Overview Dividends Analysts Charts News Strategies

Trinity Biotech Plc Sponsored ADR Class A Stock price

$1.40

-47.10 97.11% 5Y

Nasdaq, Closing price Tue, Sep 02 2025

-0.06 4.11%

ISIN

US8964383066

Symbol

TRIB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health Care Equipment & Services

Industry

Health Care Equipment & Supplies

Key metrics

Basic

Market capitalization

$26.4m

Enterprise Value

$122.0m

Net debt

$95.6m

Cash

$5.2m

Shares outstanding

30.6m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

0.4 | 0.4

EV/Sales

2.0 | 1.7

EV/FCF

negative

P/B

negative

Dividends

DPS

$0.00

Yield 1Y | 5Y

0.0% | 0.0%

Growth 1Y | 5Y

- | -

Payout 1Y | 3Y

0.0% | 0.0%

Increased

0 Years

Financials (TTM | estimate)

Revenue

$61.6m | $69.9m

EBITDA

$-16.0m | -

EBIT

$-17.9m | $-6.1m

Net Income

$-31.8m | $-28.1m

Free Cash Flow

$-14.3m

Growth (TTM | estimate)

Revenue

8.3% | 13.5%

EBITDA

-13.1% | -

EBIT

-12.2% | 61.9%

Net Income

-32.3% | 11.7%

Free Cash Flow

0.0%

Financial Health

Equity Ratio

-34.1%

Return on Equity

90.4%

ROCE

-25.1%

ROIC

-26.5%

Debt/Equity

-2.9

EPS

$-0.1

FCF per Share

$-0.5

Short interest

3.9%

Employees

380

Rev per Employee

$160.0k

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Get Started for Free Today

Trinity Biotech Plc Sponsored ADR Class A Stock Analysis

Unlock Scores for Free

??

7 Analysts have issued a Trinity Biotech Plc Sponsored ADR Class A forecast:

6x Buy

86%

More details on Analyst Estimates Including Price Targets

7 Analysts have issued a Trinity Biotech Plc Sponsored ADR Class A forecast:

Buy

86%

Hold

14%

Analyst Estimates with Stock Price Targets

Financial data from Trinity Biotech Plc Sponsored ADR Class A

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	62 62	8% 8% 100%
- Direct Costs	40 40	7% 7% 65%
Gross Profit	21 21	10% 10% 35%
- Selling and Administrative Expenses	33 33	6% 6% 54%
- Research and Development Expense	4.54 4.54	4% 4% 7%
EBITDA	-16 -16	13% 13% -26%
- Depreciation and Amortization	1.87 1.87	5% 5% 3%
EBIT (Operating Income) EBIT	-18 -18	12% 12% -29%
Net Profit	-32 -32	32% 32% -52%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Trinity Biotech Plc Sponsored ADR Class A Stock News

Neutral

GlobeNewsWire

●

one day ago

Trinity Biotech Regains Compliance with Nasdaq Listing Requirements

DUBLIN, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq Global Select: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has received written notice from the Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with the $1.00 per s...

Neutral

GlobeNewsWire

●

13 days ago

Trinity Biotech Appoints Paul Tivnan as Non-Executive Director

DUBLIN, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the appointment of Paul Tivnan to its Board of Directors as a Non-Executive Director.

Neutral

GlobeNewsWire

●

14 days ago

Regulatory Approval Granted for Commencement of Trinity Biotech's Offshored and Outsourced Manufacturing of its Flagship Rapid HIV Test, Facilitating Strategic and Financial Performance Transformation

Approval Facilitates Immediate Offshored and Outsourced Manufacturing Strategic Offshore Manufacturing Move Expected to Drive Gross Margin Expansion, Free Up Working Capital, and Enhance Scalability Transition to Outsourced Production Reduces Fixed Costs and Supports Trinity's Broader Profitability and Growth Objectives DUBLIN, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB...

More Trinity Biotech Plc Sponsored ADR Class A News

Company Profile

Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. It operates through the Americas and Rest of World geographical segments. The company was founded by Ronan O'Caoimh and Denis R. Burger in June 1992 and is headquartered in Bray, Ireland.

Head office	Ireland
CEO	John Gillard
Employees	380
Founded	1992
Website	www.trinitybiotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now